Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia.
Eviprostat has been used as a non-hormonal and non-neuropharmacological treatment for benign prostatic hyperplasia (BPH) in Japan. We evaluated the clinical efficacy of Eviprostat in patients with symptomatic BPH and the anti-inflammatory effect of this drug was investigated by retrospective evaluation of TUR specimens. Clinically, Eviprostat subjectively relieved obstructive symptoms of BPH. Objective improvements were also demonstrated by ultrasonographic evaluation of prostatic volume and urinary flow rates. Histologically, preoperative administration of Eviprostat improved the degree of prostatic inflammation. This drug probably can have a place in the treatment of patients with mild or moderate symptoms of outflow obstruction.
Ishigooka
M
M
Department of Urology, Yamagata University, School of Medicine, Japan.
Hashimoto
T
T
Hayami
S
S
Tomaru
M
M
Nakada
T
T
Mitobe
K
K
D000368:Aged; D000369:Aged, 80 and over; D004338:Drug Combinations; D004979:Ethamsylate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D011467:Prostate / Q000473:pathology; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies
D004338:Drug Combinations; D010936:Plant Extracts; D004979:Ethamsylate; C010152:eviprostat